title: From two-dimensional to three-dimensional conformal radiotherapy in prostate cancer: an Indian experience.
abstract: BACKGROUND
  Sparse data from India are available regarding the outcome of prostate cancer treatment. We report our experience in treating prostate cancer with radiotherapy (RT).
  
  
  METHODS
  This study included 159 men with locally advanced cancer treated with RT with or without hormone therapy between 1984 and 2004. The median RT dose was 70 Gy over 35 fractions. Eighty-five patients received whole pelvic RT and prostate boost, and 74 patients were treated with 3-dimensional conformal radiotherapy (3DCRT) to prostate and seminal vesicles alone.
  
  
  RESULTS
  The median follow-up was 25 months and the freedom from biochemical failure for all the patients at 5 years was 76%, disease-free survival (DFS) 59.1%, and overall survival (OAS) was 70.1%. The risk stratification (91% vs 52%, P < 0.03) and RT dose (72.8% for dose > 66 Gy vs 43.5% for dose < 66 Gy; P = 0.01) affected the DFS. DFS at 5 years was better in the group receiving 3DCRT to prostate and seminal vesicles (78% vs 51.5%; P = 0.001) and was reflected in OAS as well (P = 0.01).
  
  
  CONCLUSIONS
  CRT technique with dose escalation results in significant benefit in DFS and OAS in locally advanced prostate cancer.
authors.affiliation: Department of Radiation Oncology, Tata Memorial Centre, Mumbai, India.
authors.forename: R
authors.initials: R
authors.lastname: Engineer
authors.forename: R
authors.initials: R
authors.lastname: Bhutani
authors.forename: U
authors.initials: U
authors.lastname: Mahantshetty
authors.forename: V
authors.initials: V
authors.lastname: Murthy
authors.forename: S K
authors.initials: SK
authors.lastname: Shrivastava
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology / Q000503:physiopathology / Q000532:radiotherapy*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005500:Follow-Up Studies; D006801:Humans; D007194:India; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000473:pathology / Q000503:physiopathology / Q000532:radiotherapy*; D011832:Radiation Injuries / Q000209:etiology* / Q000517:prevention & control; D011879:Radiotherapy Dosage; D020266:Radiotherapy, Conformal / Q000009:adverse effects; D012669:Seminal Vesicles / Q000473:pathology / Q000528:radiation effects*; D016896:Treatment Outcome